-

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award is sponsored by Environment+Energy Leader, a leading publisher of environmental, energy and sustainability best practices and research.

Agilent’s Certified Pre-Owned Instruments Program gives Agilent lab customers the option to trade in their used analytical instrument for cash or toward the purchase of a new instrument. Customers can also return select decommissioned instruments to Agilent for recycling.

Agilent refurbishes used systems to new instrument standards, then resells them to customers who might not otherwise have access to high-quality instruments due to budget constraints. Systems that cannot be refurbished to Agilent’s high standards are evaluated for part reuse and recycling wherever feasible.

In fiscal year 2021, Agilent bought back over 900 used instruments from customers; sold over 3,500 certified pre-owned instruments; and took back 2,000 instruments through the program.

The Certified Pre-Owned Instruments Program is a contributor to Agilent’s Environmental, Social and Governance (ESG) focus and complements other product sustainability initiatives within the company, including designing analytical instruments to use less energy and produce less waste; product labeling that indicates the environmental footprint of select Agilent instruments; leadership in lab sustainability practices; and digital technology like CrossLab Connect that enable labs to operate more efficiently through automation, artificial intelligence, and virtual support. The initiative also advances Agilent’s commitment to achieving net-zero emissions by 2050.

Learn more about the award and Agilent’s Certified Pre-Owned Instruments and trade-in and recycling services.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC...

Agilent Showcases Next‑Generation Automated Solutions at SLAS2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency,...
Back to Newsroom